Your session is about to expire
← Back to Search
Triple Drug Therapy for Breast Cancer
Study Summary
This trial is testing a combination of three drugs to treat metastatic breast cancer that is positive for estrogen receptors, negative for human epidermal growth factor receptors, and has amplified fibroblast growth factor receptors.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My wounds heal slowly.I can swallow and keep down pills.I am fully active or restricted in physically strenuous activity but can do light work.My cancer can be measured and there's tissue available for testing.I've had more than 2 chemotherapy treatments for cancer that has spread, but any number of hormone therapies is okay.I have not had radiation therapy in the last 2 weeks.I stopped my cancer treatment (except hormone therapy) at least 1 week ago.I am not on any cancer treatments not approved in this study, but I may be taking bisphosphonates or denosumab.I have not had major surgery in the last 4 weeks.I have stopped taking herbal supplements 14 days before starting the study.I have no eye conditions that could worsen with treatment.I do not have any uncontrolled illnesses affecting my stomach, lungs, heart, or mental health.I have brain metastases that are causing symptoms.I am 18 years old or older.I am a woman who cannot become pregnant due to menopause.My breast cancer is at stage IV or cannot be removed by surgery and meets certain biomarker criteria.I have received at least one treatment for my cancer after it spread.I am currently taking medication that needs approval for this study.My blood, liver, and kidney functions meet the required levels.I have previously used an FGFR inhibitor.I have a history of chronic liver or kidney failure.
Frequently Asked Questions
Does this clinical trial have availability for new participants?
"This clinical trial is no longer accepting additional participants. This study was first posted on August 18th 2017 and last updated May 24th 2022. If you're in search of other studies, there are 2297 trials that are recruiting patients suffering from breast cancer and 247 researching the efficacy of Erdafitinib currently enrolling volunteers."
How many participants have been assigned to this research study?
"This trial is currently not enrolling new participants. It was first listed on August 18th 2017, and the most recent amendment to its listing occurred on May 24th 2022. Alternately, there are 2297 clinical trials for breast cancer that are actively seeking patients as well as 247 studies focussing on Erdafitinib."
What is the total quantity of medical centers administering this trial?
"This clinical trial has 9 sites in total, with Memorial Sloan-Kettering Cancer Center located in New york City, University of Alabama present in Birmingham and Vanderbilt-Ingram Cancer Center situated within Nashville. The other 6 locations are scattered throughout the country."
What precedent has been set by preceding trials involving Erdafitinib?
"Since its inception at Lowell General Hospital in 2004, erdafitinib has been subject to 164 completed clinical trials. Currently, 247 studies are actively recruiting participants, with a substantial number located in the city of New york."
Has Erdafitinib been authorized by the FDA?
"The safety profile of Erdafitinib has been judged to be a 1, as this is an early-stage trial with limited data on its efficacy and potential risks."
What indications are usually linked to Erdafitinib treatments?
"Erdafitinib is commonly prescribed to combat the symptoms of malignant neoplasms, as well as pik3ca gene mutation and disease progression. In some cases it may also be used in conjunction with endocrine therapy."
Share this study with friends
Copy Link
Messenger